-+ 0.00%
-+ 0.00%
-+ 0.00%

Spero Therapeutics says FDA approves Utebzi oral antibiotic for adults with complicated UTIs

PUBT·06/17/2026 16:40:02
Listen to the news
Spero Therapeutics says FDA approves Utebzi oral antibiotic for adults with complicated UTIs
  • FDA cleared Utebzi (tebipenem pivoxil) to treat adults with complicated UTIs, including pyelonephritis, when oral options are limited.
  • First oral carbapenem antibiotic approved in the US; GSK holds exclusive global rights under its licensing deal with Spero Therapeutics.
  • Approval backed by Phase III PIVOT-PO data showing non-inferiority versus IV imipenem-cilastatin; US launch expected by end-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief on June 17, 2026, and is solely responsible for the information contained therein.